Search Results
Your search for The ASCO ,The ASCO matches 21408 pages
Showing 14901 - 14950Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, according to researchers at The University of Texas MD Anderson Cancer Center. Chen et al reported their findings in...
Report Tracks Cancer Trends by Race/Ethnicity in Los Angeles County for 37 Years
Prostate cancer and lung cancer have been the number 1 and 2 cancers among men. Stomach cancer, the third leading cause of cancer deaths worldwide, has been on a steady decline among Koreans and Japanese. Black men had the highest overall rates of cancer. Thyroid cancer has been on the rise, and...
New SSO, ASTRO, and ASCO Joint DCIS Consensus Guideline Could Curb Unnecessary Breast Surgery and Reduce Health System Costs
Three leading national cancer organizations have issued a consensus guideline for physicians treating women who have ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole breast irradiation. The new guideline has the potential to save many women from unnecessary...
Obesity on the Rise in Adults With a History of Cancer
A study at Columbia University's Mailman School of Public Health showed that obesity was more prevalent in patients with a history of cancer than in the general population, and survivors of colorectal and breast cancers were particularly affected. The study is among the first to compare rates of...
Needle Biopsies for Noninvasive Breast Cancer: Routine Analysis Wastes Millions
For patients with the most common type of noninvasive breast cancer, routine testing for estrogen and progesterone receptors in tissue taken at the first needle biopsy is both unnecessary and wasteful, according to results of a study led by Johns Hopkins pathologists. The results for people with...
Study Finds United States Ranks First in Health-Care Spending, but Cancer Outcomes Do Not Reflect the Investment
The U.S. health-care system is characterized—on a global level—by its unsustainable spending, which does not necessarily correlate to better outcomes in patients with cancer. With $2.9 trillion spent in 2013, the United States ranks first in health-care spending among the world’s...
Metabolic Imaging as a Method to Assess Treatment Response to Cytotoxic and Cytostatic Agents
Tumor shrinkage is not the only measure of a successful anticancer therapy. A University of Colorado Cancer Center article published by Serkova et al in Frontiers in Oncology describes a promising alternative: metabolic imaging. Tumors rush their metabolism to grow and proliferate. By recognizing a ...
Study Identifies Novel Treatment Resistance Mechanism in BRAF-Mutant Melanoma
A Massachusetts General Hospital (MGH) research team has identified an additional mechanism for resistance to targeted treatment for BRAF-mutant melanoma. Their findings, published by Shen et al in Nature Medicine, report that inactivating mutations in two genes responsible for regulating key...
FDA Grants Orphan Drug Designation to CD4CAR for the Treatment of Peripheral T-Cell Lymphoma
iCell Gene Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). William Tse, MD,...
CA-125 Tests and CT Scans Still Routinely Used for Surveillance in Ovarian Cancer, Yet Benefit Remains Unproved
As reported by Esselen et al in JAMA Oncology, cancer antigen 125 (CA-125) tests and computed tomography (CT) scans for surveillance in women with ovarian cancer continue to be used routinely, although their benefit has not been proven and the practices have significant quality-of-life and economic ...
New American Cancer Society Cancer Action Network Report Shows States Are Making Progress Implementing Policies to Reduce Toll of Cancer
Although a majority of states are still missing important opportunities to pass and implement legislative solutions proven to prevent and fight cancer, there is progress being made to move the nation closer to ending cancer as we know it, according to a report recently released by the American...
New Study Shows Breast Tumors May Evolve in Response to Hormone Therapy
Many breast tumors grow in response to female hormones, especially estrogen. Drugs that reduce estrogen levels in the body often are effective in reducing tumor size and preventing recurrence of the cancer. But some tumors become resistant to these therapies and continue to grow and spread. A new...
Similar Functional Outcomes Reported With Robot-Assisted Laparoscopic and Open Radical Retropubic Prostatectomy
Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar domain-specific quality-of-life or pathologic outcomes at 12 weeks in men with newly diagnosed, clinically localized prostate cancer, according to the results of a randomized phase III trial reported ...
FDA Approves Extended-Release Granisetron Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Heron Therapeutics, Inc, announced on August 10, 2016, that the U.S. Food and Drug Administration (FDA) has approved granisetron (Sustol) extended-release injection. Granisetron is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention ...
Higher Exposure to Radical Local Treatment Linked to Lower Mortality in Men With Very High-Risk Prostate Cancer
Men with very high-risk prostate cancer treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy) have half of the mortality risk of men who are treated at hospitals with the lowest proportions, according to a new study conducted by...
Nivolumab Did Not Meet Primary Endpoint of Progression-Free Survival in NSCLC in CheckMate-026 Trial
Bristol-Myers Squibb Company announced last week that CheckMate-026, a phase III trial investigating the use of nivolumab (Opdivo) as monotherapy, did not meet its primary endpoint of progression-free survival in patients with previously untreated advanced non–small cell lung cancer (NSCLC)...
Insurance Status Impacts Survival, According to Two New Studies
Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study found. The findings, published by Markt et al in Cancer, add to growing evidence that differences in health insurance status can affect...
ASCO and SGO Issue New Guideline on Ovarian Cancer Treatment
ASCO and the Society of Gynecologic Oncology (SGO) today issued a joint clinical practice guideline on ovarian cancer treatment. The guideline provides evidence-based recommendations on whether to use neoadjuvant chemotherapy or surgery as the initial treatment for women with stage IIIC and IV...
Internationally Renowned Geneticist, Alfred George Knudson, MD, PhD, Dies
Considered a visionary in cancer research, Alfred George Knudson, MD, PhD, was internationally recognized for his “two-hit theory” of cancer causation, which explained the relationship between hereditary and nonhereditary cancer types, predicting the existence of tumor suppressor genes. Dr. Knudson ...
Dabrafenib Plus Trametinib in BRAF V600E–Mutant Metastatic NSCLC
In a phase II trial reported in The Lancet Oncology, Planchard et al found that combined MAPK pathway inhibition with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) resulted in a high response rate in patients with BRAF V600E–mutant non–small cell lung cancer...
Adding Pertuzumab to Chemotherapy in Platinum-Resistant Ovarian Cancer
According to the European phase III PENELOPE trial reported in the Journal of Clinical Oncology, Christian Kurzeder, MD, of Kliniken Essen-Mitte, Essen, Germany, et al found that adding pertuzumab (Perjeta) to investigator’s choice chemotherapy did not improve progression-free survival in women...
Ipilimumab Combined With Antigen-Specific Cytotoxic T Lymphocytes in Metastatic Melanoma
In a study reported in the Journal of Clinical Oncology by Chapuis et al, concurrent use of cytotoxic T lymphocyte (CTL) antigen-4 (CTLA-4) blockade with ipilimumab (Yervoy) and adoptively transferred antigen-specific CTLs produced enduring responses in patients with stage IV melanoma. Cassian Yee, ...
Low-Dose CT Screening: New Solid Nodules and Lung Cancer Probability
As reported by Walter et al in The Lancet Oncology, incidence screening with low-dose computed tomography (CT) in high-risk individuals detected new solid nodules in approximately 5% to 7% at second and third screenings in the ongoing Dutch-Belgian NELSON trial. Larger nodule size was associated...
Anti–PD-L1 Antibody Durvalumab in Advanced Urothelial Bladder Cancer
In a phase I/II study reported in the Journal of Clinical Oncology, Massard et al found that the anti–PD-L1 (programmed cell death ligand 1) antibody durvalumab was active in patients with previously treated advanced urothelial bladder cancer. Objective response appeared to be confined to patients...
Quality of Life With Nivolumab vs Everolimus in Advanced Renal Cell Carcinoma
Patients with previously treated advanced renal cell carcinoma receiving nivolumab (Opdivo) in the phase III CheckMate 025 trial had improved health-related quality of life compared with those receiving everolimus (Afinitor), as reported by David Cella, PhD, of Northwestern University, Chicago, et...
Final Results of METEOR Trial: Cabozantinib vs Everolimus in Advanced Renal Cell Carcinoma
As reported by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma...
Pancreatic Cancer Action Network Appoints Four Leaders to Its Scientific and Medical Advisory Board
The Pancreatic Cancer Action Network has added four leaders from across the country to its Scientific and Medical Advisory Board. “Members of the Pancreatic Cancer Action Network Scientific and Medical Advisory Board have committed their careers to change the course of a deadly and complex...
ASTRO Members Elect Five New Officers to Board of Directors
Members of the American Society for Radiation Oncology (ASTRO) have elected five new officers to the Society’s Board of Directors, including President-Elect, Secretary/Treasurer-Elect, and Vice-Chairs of three of ASTRO’s five councils (Clinical Affairs and Quality, Education, and Government...
Multiple Strategies for Colorectal Cancer Screening Offer an Opportunity for Shared Decision-Making
Screening for colorectal cancer should start at age 50 and continue until age 75, according to the updated recommendation from the U.S. Preventive Services Task Force (USPSTF).1 “Exactly what screening gets done is something that doctors and patients should decide together,” USPSTF Chair Kirsten...
Multiple Means to Realize the Benefits of Colorectal Cancer Screening
In an updated recommendation statement, the U.S. Preventive Services Task Force (USPSTF) continues to strongly recommend screening for colorectal cancer for asymptomatic adults aged 50 through 75; but rather than emphasize specific screening strategies, it notes there are multiple screening...
Study Shows Women Who Received Cancer Screening Invitation Letters Are More Likely to Have a Pap Test
Receiving an invitation to get screened for cervical cancer is associated with a greater likelihood of getting screened, according to a study published by Tavasoli et al in Preventive Medicine. The study explored the impact of invitation and reminder letters on cervical cancer screening...
FDA Approves Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Platinum-Containing Chemotherapy
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, at a fixed dose of 200 mg every 3 weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with...
Julienne Bower, PhD, Named Professor of Psychobiology in Cousins Center for Psychoneuroimmunology at UCLA
The Cousins Center for Psychoneuroimmunology at the University of California, Los Angeles (UCLA) Semel Institute for Neuroscience and the UCLA Jonsson Comprehensive Cancer Center (JCCC) announced that Julienne Bower, PhD, Co-Director of the JCCC Patients and Survivors Program, Professor of...
The Building Block of Life, Brick by Brick
BookmarkTitle: The Gene: An Intimate HistoryAuthor: Siddhartha Mukherjee, MDPublisher: ScribnerPublication date: May 2016Price: $32.00; hardcover, 608 pagesOn February 28, 1953, James Watson and Francis Crick entered The Eagle, a favorite watering hole for researchers working at the University of...
David LeDuc Named Executive Director of Addario Lung Cancer Foundation
The Bonnie J. Addario Lung Cancer Foundation (ALCF) has announced that it has appointed David LeDuc as its new Executive Director. Mr. LeDuc most recently served as the Senior Director of Strategic Alliances for the Addario Lung Cancer Medical Institute (ALCMI), a partner foundation to ALCF, where ...
Reference Laboratory Identifies Change in Pattern of Breast Cancer HER2 Fluorescence in Situ Hybridization Results
The most recent (2013) ASCO/College of American Pathologists (AC) guidelines for HER2 testing resulted in different rates of HER2 positivity compared with the use of the U.S. Food and Drug Administration (FDA) or 2007 AC guidelines, according to a study reported in the Journal of Clinical Oncology...
Integrating Early Palliative Medicine Into Oncology Care to Improve Patients’ Quality of Life
At the 2015 Palliative Care in Oncology Symposium in Boston, Vicki Jackson, MD, MPH, Chief in the Division of Palliative Care and Geriatrics at Massachusetts General Hospital, Co-Director of the Harvard Center for Palliative Care, and Associate Professor of Medicine at Harvard Medical School,...
ASH Commits $3 Million Annually to Help Preserve Critical Blood Disease Research
With a $3 million annual commitment to support promising blood disease research amid limited National Institutes of Health (NIH) funding, the American Society of Hematology (ASH) has announced the formal establishment of the ASH Bridge Grant program after an extended 4-year pilot study. ASH also...
FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection
The U.S. Food and Drug Administration (FDA) approved Epclusa (sofosbuvir at 400 mg/velpatasvir at 100 mg) on June 28, 2016, to treat adult patients with chronic hepatitis C virus both with and without cirrhosis. For patients with moderate to severe cirrhosis (decompensated cirrhosis),...
FDA Approves First HPV Test for Use With SurePath Preservative Fluid
On July 7, 2016, the U.S. Food and Drug Administration (FDA) approved the Roche cobas HPV Test as the first test for human papillomavirus (HPV) that can be used with cervical cells obtained for a Papanicolau (Pap) test and collected in SurePath Preservative Fluid. The FDA approves HPV tests to be...
Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial After FDA Clinical Hold
Juno Therapeutics, Inc., announced on July 12, 2016, that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the phase II clinical trial of JCAR015 (known as the ROCKET trial; clinicaltrials.gov identifier NCT02535364) in adult patients with relapsed or refractory B-cell...
NCCN Imaging Appropriate Use Criteria to Be Integrated Into National Decision Support Company’s CareSelect Imaging
The National Comprehensive Cancer Network® (NCCN) is collaborating with National Decision Support Company (NDSC) to integrate the NCCN Imaging Appropriate Use Criteria (AUC) into NDSC’s CareSelect Imaging to allow for access to imaging recommendations, adapted from the NCCN Clinical Practice...
Maryland Proton Treatment Center Appoints Charles B. Simone II, MD, New Medical Director
Charles B. Simone II, MD, has been named the new Medical Director of the Maryland Proton Treatment Center (MPTC). Dr. Simone will begin work in November 2016. As Medical Director, Dr. Simone will continue to define and implement processes ensuring that MPTC is integrated into the radiation...
NCI Awards $12 Million for Multi-Institution Breast Cancer Genetics Study
A large study headed by researchers from the Keck School of Medicine of the University of Southern California (USC), Vanderbilt University, and Boston University received $12 million in funding to examine why African American women die at a higher rate from breast cancer and have more aggressive...
Epithelial Cells on the Tail Fin of Genetically Engineered Zebrafish
Image depicts hundreds of live cells from a tiny bit of skin on the tail fin of a genetically engineered adult zebrafish. The cells have been labeled with a new fluorescent imaging tool called Skinbow. It uniquely color codes cells by getting them to express genes encoding red, green, and blue...
New Analysis Shows Advertising by U.S. Cancer Centers Has Soared Over Past Decade
American cancer centers promoting their services dramatically increased their advertising spending from 2005 to 2014, with the bulk of the spending by for-profit organizations, according to the results of a study published by Vater et al in JAMA Internal Medicine.1 Small Percentage Responsible for...
Actively Recruiting Clinical Trials Focused on the Role of Obesity in Cancer
Study Title: A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors Study Type: Pilot/interventional/single-group assignment Study Sponsor and Collaborators: Case Comprehensive Cancer Center, National Cancer Institute Purpose: To study whether the...
2016 - 2017 Oncology Meetings
AUGUST The 33rd World Congress of Internal Medicine (WCIM)August 22-25 • Bali, IndonesiaFor more information: www.wcimbali2016.org 16th World Congress on Cancers of the SkinAugust 31-September 3 • Vienna, Austria For more information: www.wccs2016.com 12th National Lymphedema Network International...
13 Mid-Career Clinical Investigators Receive 2016 NCI Cancer Clinical Investigator Team Leadership Award
At the National Cancer Institute (NCI) Clinical Trials and Translational Research Advisory Committee (CTAC) meeting held on July 13, 2016, 13 recipients were presented with the 2016 NCI Cancer Clinical Investigator Team Leadership Award (CCITLA). The award recognizes and supports outstanding...
OmniSeq Receives New York CLEP Approval for 144-Gene Comprehensive Panel, Partners With Cure Forward
OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq Comprehensive panel, a 144-gene, pan-cancer, next-generation sequencing tumor-profiling diagnostic panel to guide oncology treatment...
